Pre-clinical regulatory compliance activities

Like other potential biopharmaceutical products, FDA, Center for Biologies Evaluation and Research (CBER) regulates the production, testing and use of AAV vectors in human clinical trials, in the US. Many regulatory documents are available to help guide the researcher. These documents are available via the Internet on http //www.fda.gov.cber/guidelines.htm. Review of these documents prior to significant work towards production of vector for 

ADENO-ASSOCIATED VIRUS VECTORS FOR GENE THERAPY 

Characterization of the vector batch used in non-clinical safety studies is also performed in compliance with GLPs. Care should be taken to ensure that adequate and appropriate processes are used to produce the batch(es) required, and the production process should be similar to that proposed for production of the vector for human clinical trials, or at least performed in such a way that adequate documentation of the production methods is available for comparative purposes. The GLP regulations state that the identity, purity, and composition of the vector batch (test article) used in a safety study must be known and documented. In addition, the stability of the vector preparation in the specific container used for the study must also be known prior to initiation of the study or acquired concomitantly with the study itself. These test article characterization experiments require that the researcher produce additional amounts of vector identical to the material used in 

Characterization of AAV vector batches used in animal safety studies 

Potency-infectious titer Strength-particle/genome titer Protein purity 

---